NCT01089907

Brief Summary

To study the genomics with cell cycle and lymphocyte differentiation in disease, remission and relapse of childhood acute lymphoblastic leukemia. Then correlate these data with age, white cell count, cytogenetic changes, response to the chemotherapy and prognosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2010

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 17, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 19, 2010

Completed
13 days until next milestone

Study Start

First participant enrolled

April 1, 2010

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

March 19, 2010

Status Verified

March 1, 2010

Enrollment Period

2.8 years

First QC Date

March 17, 2010

Last Update Submit

March 18, 2010

Conditions

Acute Lymphoblastic Leukemia

Keywords

genomicchildhoodacute lymphoblastic leukemia

Eligibility Criteria

Age1 Day - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Acute lymphoblastic leukemia patients under 18 years of age

You may qualify if:

  • patients diagnosed as acute lymphoblastic leukemia
  • age less than or equal to 18 years old
  • signed informed consent

You may not qualify if:

  • who is not acute lymphoblastic leukemia
  • who did not sign informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

bone marrow, peripheral blood

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Dong-Tsamn Lin, M.D.

    National Taiwan University Hospital,Taipei,Taiwan

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dong-Tsamn Lin, M.D.

CONTACT

02-23123456dtlin@ntuh.gov.tw

young-li Yang, M.D.

CONTACT

02-23123456yangylmd@gmail.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 17, 2010

First Posted

March 19, 2010

Study Start

April 1, 2010

Primary Completion

January 1, 2013

Study Completion

June 1, 2013

Last Updated

March 19, 2010

Record last verified: 2010-03

Locations

TW(1)